Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma

Pazopanib is approved for treatment of advanced soft tissue sarcomas, but primary and secondary drug resistance limits its clinical utility. We investigated the molecular mechanisms mediating pazopanib resistance in human synovial sarcoma (SS) models. We found reduced cell sensitivity to pazopanib a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Lanzi, Cinzia, Dal Bo, Laura, Favini, Enrica, Tortoreto, Monica, Beretta, Giovanni Luca, Arrighetti, Noemi, Zaffaroni, Nadia, Cassinelli, Giuliana
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6468361/
https://ncbi.nlm.nih.gov/pubmed/30909453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11030408
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky